Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

20091,152 citationsJournal Articlebronze Open Access

Authors

In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value. BRAF is prognostic for OS in MS-L/S tumors.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 28, Issue 3, pp. 466-474

Field-Weighted Citation Impact: 34.25